Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586047 · ClinicalTrials.gov registry record · NA
Breast Cancer PSMA PET
A NA study of Triple Negative Breast Cancer, sponsored by Ahmad Shariftabrizi.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06586047: Recruiting NA study of Triple Negative Breast Cancer, sponsored by Ahmad Shariftabrizi.
NCT06586047 is a NA study of Triple Negative Breast Cancer that is actively recruiting participants, run by Ahmad Shariftabrizi. The registered enrollment target is 30 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06586047, a NA study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Ahmad Shariftabrizi.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Primary Outcome
Comparing the sensitivity of 18 F-DCFPyL-PET/CT and FDG PET/CT in metastatic lesion detection in triple-negative breast cancer patients.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PET imaging
Study Locations (1)
Iowa
- University of Iowa Healthcare - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-29 |
| Est. Completion | 2026-08-29 |
| Phase | NA |
What NCT06586047 shows while recruiting
NCT06586047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PET imaging is the first listed.
NCT06586047 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06586047 about?
NCT06586047 is a clinical study titled "Breast Cancer PSMA PET". The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA...
What is the current status of trial NCT06586047?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-08-29. Estimated completion is 2026-08-29.
What conditions does trial NCT06586047 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT06586047?
The interventions under investigation include: PET imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06586047?
This trial is sponsored by Ahmad Shariftabrizi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586047 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06586047's enrollment target sits among peer trials
30 93rd of 118 higher than 21 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
RECRUITING · NA
-
TNBC Gut Microbiota During Neoadjuvant Treatment
RECRUITING · NA
-
Cardiac Outcomes With Near-Complete Estrogen Deprivation
RECRUITING · NA
-
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
RECRUITING · NA
-
Emotions Immunology and Breast Cancer
COMPLETED · NA
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI